T2 Biosystems Inc Share Price TTOO

Last updated on May 6, 2026 at 1:20 am IST

$₹

Check the interactive T2 Biosystems Inc Stock chart to analyse performance

T2 Biosystems Inc Key Stats

Check T2 Biosystems Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$0.003
Open	$6.0E-4
Market Capitalization	$14.0K
Today's Volume	$1.6M
Revenue TTM	$7.7M
EBITDA	$-41.4M
Earnings Per Share (EPS)	$-0.03
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-622.14%

Stock Returns calculator for T2 Biosystems Inc Stock including INR - Dollar returns

The T2 Biosystems Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

T2 Biosystems Inc investment value today

Current value as on today

Returns

(0%)

Returns from T2 Biosystems Inc Stock

(0%)

Dollar Impact

(0%)

Global Institutional Holdings in T2 Biosystems Inc

Name
Holdings %
Name
Holdings %
Armistice Capital, LLC
4.98%
Vanguard Group Inc
1.39%
Geode Capital Management, LLC
0.32%
BlackRock Inc
0.27%
State Street Corp
0.23%
Susquehanna International Group, LLP
0.16%

Analyst Recommendation on T2 Biosystems Inc Stock

Rating

Trend

Sell

0%Buy

50%Hold

50%Sell

Based on 6 Wall street analysts offering stock ratings for T2 Biosystems Inc(by analysts ranked 0 to 5 stars)

T2 Biosystems Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY18

FY19

FY20

FY21

FY22

FY23

	FY18	Y/Y Change
Revenue	$10.5M	↑ 125.03%
Net Income	$-51.2M	↓ 18.06%
Net Profit Margin	-487.17%	↑ 850.76%

	FY19	Y/Y Change
Revenue	$8.3M	↓ 20.62%
Net Income	$-63.1M	↑ 23.38%
Net Profit Margin	-757.19%	↓ 270.02%

	FY20	Y/Y Change
Revenue	$18.1M	↑ 117.52%
Net Income	$-49.2M	↓ 22.03%
Net Profit Margin	-271.42%	↑ 485.77%

	FY21	Y/Y Change
Revenue	$28.1M	↑ 54.76%
Net Income	$-53.5M	↑ 8.71%
Net Profit Margin	-190.66%	↑ 80.76%

	FY22	Y/Y Change
Revenue	$22.3M	↓ 20.5%
Net Income	$-63.4M	↑ 18.46%
Net Profit Margin	-284.11%	↓ 93.45%

	FY23	Y/Y Change
Revenue	$7.2M	↓ 67.75%
Net Income	$-50.1M	↓ 20.98%
Net Profit Margin	-696.19%	↓ 412.08%

Q2 FY23

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

	Q2 FY23	Q/Q Change
Revenue	$2.0M	↓ 5.49%
Net Income	$-6.3M	↓ 68.33%
Net Profit Margin	-323.17%	↑ 641.17%

	Q3 FY23	Q/Q Change
Revenue	$1.5M	↓ 25.05%
Net Income	$-15.4M	↑ 143.03%
Net Profit Margin	-1.0K%	↓ 724.72%

	Q4 FY23	Q/Q Change
Revenue	$1.7M	↑ 14.06%
Net Income	$-10.3M	↓ 32.97%
Net Profit Margin	-615.84%	↑ 432.05%

	Q1 FY24	Q/Q Change
Revenue	$2.1M	↑ 22.75%
Net Income	$-13.5M	↑ 30.89%
Net Profit Margin	-656.67%	↓ 40.83%

	Q2 FY24	Q/Q Change
Revenue	$2.0M	↓ 5.29%
Net Income	$-9.0M	↓ 33.77%
Net Profit Margin	-459.17%	↑ 197.5%

	Q3 FY24	Q/Q Change
Revenue	$2.0M	↑ 1.69%
Net Income	$-10.1M	↑ 12.88%
Net Profit Margin	-509.67%	↓ 50.5%

FY18

FY19

FY20

FY21

FY22

FY23

	FY18	Y/Y Change
Profit	$-4.9M	↓ 33.39%

	FY19	Y/Y Change
Profit	$-8.4M	↑ 71.86%

	FY20	Y/Y Change
Profit	$-3.2M	↓ 62.62%

	FY21	Y/Y Change
Profit	$7.4M	↓ 333.49%

	FY22	Y/Y Change
Profit	$1.2M	↓ 84.15%

	FY23	Y/Y Change
Profit	$-8.2M	↓ 800.69%

Q2 FY23

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

	Q2 FY23	Q/Q Change
Profit	$-2.9M	↑ 51.54%

	Q3 FY23	Q/Q Change
Profit	$-2.5M	↓ 15.56%

	Q4 FY23	Q/Q Change
Profit	$-895.0K	↓ 63.51%

	Q1 FY24	Q/Q Change
Profit	$-2.1M	↑ 139.22%

	Q2 FY24	Q/Q Change
Profit	$-741.0K	↓ 65.39%

	Q3 FY24	Q/Q Change
Profit	$-2.1M	↑ 185.56%

FY18

FY19

FY20

FY21

	FY18	Y/Y Change
Operating Cash Flow	$-40.1M	↓ 15.88%
Investing Cash Flow	$-593.0K	↓ 76.05%
Financing Cash Flow	$49.7M	↑ 168.34%

	FY19	Y/Y Change
Operating Cash Flow	$-45.4M	↑ 13.01%
Investing Cash Flow	$-761.0K	↑ 28.33%
Financing Cash Flow	$6.4M	↓ 87.21%

	FY20	Y/Y Change
Operating Cash Flow	$-43.2M	↓ 4.73%
Investing Cash Flow	$-36.3M	↑ 4664.91%
Financing Cash Flow	$85.6M	↑ 1248.14%

	FY21	Y/Y Change
Operating Cash Flow	$-38.9M	↓ 10.05%
Investing Cash Flow	$24.8M	↓ 168.37%
Financing Cash Flow	$20.5M	↓ 76.01%

Q2 FY23

Q3 FY23

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-12.4M	↓ 4.27%
Investing Cash Flow	$-33.0K	↑ 0.0%
Financing Cash Flow	$18.4M	↑ 55.19%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-13.4M	↑ 8.12%
Investing Cash Flow	$-13.0K	↓ 60.61%
Financing Cash Flow	$21.6M	↑ 17.7%

About T2 Biosystems Inc

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Organization	T2 Biosystems Inc
Employees	113
CEO	Mr. John J. Sperzel III, B.Sc.
Industry	Health Technology

Key Management of T2 Biosystems Inc

Name	Title
Mr. John J. Sperzel III, B.Sc.	President, CEO & Chairman
Mr. John M. Sprague CPA	Chief Financial Officer
Mr. Michael Terrence Gibbs Esq.	Senior VP, General Counsel & Company Secretary
Ms. Kelley J. Morgan	Chief People Officer
Mr. Brett A. Giffin	Chief Commercial Officer
Dr. Roger Smith Ph.D.	Senior Vice President of Science Research & Development

Important FAQs about investing in TTOO Stock from India :

What is T2 Biosystems Inc share price today?

T2 Biosystems Inc share price today is as on May 6, 2026 at 1:20 am IST at the close of the market. T2 Biosystems Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for T2 Biosystems Inc share?

T2 Biosystems Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. T2 Biosystems Inc stock price today i.e. May 6, 2026 at 1:20 am IST is closed at , lower by 100% versus the 52 week high.

How to invest in T2 Biosystems Inc Stock (TTOO) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for T2 Biosystems Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in T2 Biosystems Inc Shares .

What is the minimum amount required to buy T2 Biosystems Inc Stock (TTOO) from India?

Indian investors can start investing in T2 Biosystems Inc (TTOO) shares with as little as ₹95.37 or $1 (as of May 06, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹953.70 in T2 Biosystems Inc stock (as per the Rupee-Dollar exchange rate as on May 06, 2026). Learn more about fractional shares .

What are the returns that T2 Biosystems Inc has given to Indian investors in the last 5 years?

T2 Biosystems Inc stock has given -100.0% share price returns and 29.56% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Sangamo Therapeutics, Inc.
$0.11
-38.89%
Ategrity Specialty Holdings
$19.25
+0.47%
Small Cap Growth ETF Vanguard
$341.80
+1.14%
RANGE CAPITAL ACQUISIT CL A
$10.02
-0.1%
Restoration Hardware Holdings, Inc.
$123.53
+0.96%
Aberdeen India Fund Inc
$11.74
-0.76%
Paramount Gold Nevada Corp
$1.39
+0.72%
ADVENT CONVERTIBLE BOND ETF
$27.32
+0.04%
RCKEFLLR GBL EQT ETF
$33.35
+1.12%

Explore all